BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30563651)

  • 1. Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
    Beksac AT; Cumarasamy S; Falagario U; Xu P; Takhar M; Alshalalfa M; Gupta A; Prasad S; Martini A; Thulasidass H; Rai R; Berger M; Hectors S; Jordan J; Davicioni E; Nair S; Haines K; Lewis S; Rastinehad A; Yadav K; Jayaratna I; Taouli B; Tewari A
    J Urol; 2018 Dec; 200(6):1241-1249. PubMed ID: 30563651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics Features Measured with Multiparametric Magnetic Resonance Imaging Predict Prostate Cancer Aggressiveness.
    Hectors SJ; Cherny M; Yadav KK; Beksaç AT; Thulasidass H; Lewis S; Davicioni E; Wang P; Tewari AK; Taouli B
    J Urol; 2019 Sep; 202(3):498-505. PubMed ID: 30958743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer.
    Rayn KN; Bloom JB; Gold SA; Hale GR; Baiocco JA; Mehralivand S; Czarniecki M; Sabarwal VK; Valera V; Wood BJ; Merino MJ; Choyke P; Turkbey B; Pinto PA
    J Urol; 2018 Nov; 200(5):1041-1047. PubMed ID: 29852182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.
    Salmasi A; Said J; Shindel AW; Khoshnoodi P; Felker ER; Sisk AE; Grogan T; McCullough D; Bennett J; Bailey H; Lawrence HJ; Elashoff DA; Marks LS; Raman SS; Febbo PG; Reiter RE
    J Urol; 2018 Sep; 200(3):564-572. PubMed ID: 29524506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
    Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
    J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy.
    Bianchi R; Cozzi G; Petralia G; Alessi S; Renne G; Bottero D; Brescia A; Cioffi A; Cordima G; Ferro M; Matei DV; Mazzoleni F; Musi G; Mistretta FA; Serino A; Tringali VML; Coman I; De Cobelli O
    Medicine (Baltimore); 2016 Oct; 95(40):e4519. PubMed ID: 27749525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
    Stonier T; Tin AL; Sjoberg DD; Jibara G; Vickers AJ; Fine S; Eastham J
    J Urol; 2021 Apr; 205(4):1063-1068. PubMed ID: 33216696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system.
    Alqahtani S; Wei C; Zhang Y; Szewczyk-Bieda M; Wilson J; Huang Z; Nabi G
    Sci Rep; 2020 May; 10(1):7722. PubMed ID: 32382097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
    Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
    Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
    Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
    Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gleason Score within Prostate Abnormal Areas Defined by Multiparametric Magnetic Resonance Imaging Did Not Vary According to the PIRADS Score.
    Slaoui H; Neuzillet Y; Ghoneim T; Rouanne M; Abdou A; Lugagne-Delpon PM; Scherrer A; Radulescu C; Delancourt C; Molinié V; Lebret T
    Urol Int; 2017; 99(2):156-161. PubMed ID: 28391284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
    J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
    Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
    Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-gantry MRI guided prostate biopsy diagnosis of prostatitis and its relationship with PIRADS V.2 based score.
    Jyoti R; Jina NH; Haxhimolla HZ
    J Med Imaging Radiat Oncol; 2017 Apr; 61(2):212-215. PubMed ID: 27987276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric magnetic resonance imaging identifies significant apical prostate cancers.
    Kenigsberg AP; Tamada T; Rosenkrantz AB; Llukani E; Deng FM; Melamed J; Zhou M; Lepor H
    BJU Int; 2018 Feb; 121(2):239-243. PubMed ID: 28805295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy.
    Pal RP; Ahmad R; Trecartan S; Voss J; Ahmed S; Bazo A; Lloyd J; Walton TJ
    J Urol; 2018 Aug; 200(2):302-308. PubMed ID: 29477717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy.
    Falagario UG; Ratnani P; Lantz A; Jambor I; Dovey Z; Verma A; Treacy PJ; Sobotka S; Martini A; Bashorun H; Ashan M; Wagaskar VG; Lewis S; Cormio L; Carrieri G; Kyprianou N; Mohamed N; Tewari A
    J Urol; 2020 Jul; 204(1):82-90. PubMed ID: 31977261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.